For Quick Alerts
For Daily Alerts

New Therapy To Treat Inoperable Melanoma

By Super

A study at University of Pittsburgh Cancer Institute (UPCI) has cited that the combination of two different biotherapies may turn out to be more beneficial for patients with inoperable melanoma.

The researchers used two biotherapies, treatments that stimulate the immune system to fight cancer, and found that the results were quite promising in terms of anti-tumor effects and tolerable in terms of toxicity.

It was the first time that the researchers combined two biotherapies in this phase 2 trial. The biotherapies were: High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the body"s immune system.

“With each new study, we learn something important about melanoma. With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting," said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine.

In the study, the combination treatment was given to 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy

It was found that the overall response rate was 19 percent, and after that the study entered the second stage, where it will enroll 21 patients more.

Melanoma is a rare form of skin cancer, causing the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure.

In case of patients with inoperable disease, like those enrolled in this study, such discovery of a safe and effective treatment holds a big importance.

The study was presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Boldsky sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Boldsky website. However, you can change your cookie settings at any time. Learn more